Energenesis Biomedical: Bringing New Dimension to Wound Healing Care

Dr. Chen Han-min, Vice Chairman/General Manager Wound healing is a complex, biological process that is critical in maintaining the skin’s barrier function. The healing of wounds is controlled by many factors such as oxygenation, blood circulation, and diabetes, to name a few. Due to which, the time taken to heal different type of wounds differs. Some wounds get healed quickly, while others may take longer, mainly depending on the severity of wounds or the health condition of that individual. The slow healing process leads to poor medical outcomes and lowers the quality of life for the patients. To that end, effective wound healing agents and comprehensive care are crucial for those populations. Although there are several medical devices, surgical treatments, and cell therapies to treat wounds, when it comes to safe and effective drugs, there are hardly any in the market. Moreover, the on-demand medical devices used for wound healing only provide a coverage or protection for healing and, in some cases, are susceptible to infection. Cell therapy and tissue engineering technologies are not only expensive but also inconvenient, which rely on professional caretaker to operate and affect patient compliance.

Identified a massive void in the wound care market, Energenesis Biomedical, a renowned biotech company from Taiwan, decided to build the bridge by developing a new drug with the unique small molecule compound, ENERGI-F703, whose concept of accelerating the wound healing process has been proved. ENERGI-F703 is a gel used in accelerating chronic wounds’ healing, mainly by activating the AMPK inside cells to boost the amount of intracellular adenosine triphosphate (ATP), energy molecules, in tissues near the wounds. Due to its inherent characteristics, ENERGI-F703, meets regulations, has no safety issues, and targets the niche market of wound healing as a prescription drug..